PMID- 18494613
OWN - NLM
STAT- MEDLINE
DCOM- 20080703
LR  - 20151119
IS  - 1365-2559 (Electronic)
IS  - 0309-0167 (Linking)
VI  - 52
IP  - 7
DP  - 2008 Jun
TI  - Tissue microarray technology in the routine assessment of HER-2 status in 
      invasive breast cancer: a prospective study of the use of immunohistochemistry 
      and fluorescence in situ hybridization.
PG  - 847-55
LID - 10.1111/j.1365-2559.2008.03047.x [doi]
AB  - AIMS: To compare tissue microarray (TMA) and whole-section (WS) techniques in the 
      routine assessment of HER-2 status in invasive breast cancer by 
      immunohistochemistry and fluorescence in situ hybridization (FISH). METHODS AND 
      RESULTS: HER-2 status was assessed prospectively in 106 consecutive cases of 
      excised high-grade and/or node-positive breast carcinoma using both WS- and 
      TMA-based techniques. Whole sections were assessed by immunohistochemistry with 
      FISH being performed on equivocal cases (scoring 2+ on HercepTest) and randomly 
      selected 3+ cases included for quality assurance. Five 0.6-mm cores from each 
      tumour allowed accurate immunohistochemical and FISH testing in >95% of cases. 
      Ninety-seven per cent concordance was achieved between WS and TMA approaches to 
      FISH analysis, the only discrepancies being in cases that were borderline or near 
      borderline by both techniques. TMA and WS approaches were comparable in terms of 
      time for preparation and scoring. CONCLUSIONS: TMA technology is a robust method 
      of assessing HER-2 status in invasive breast cancer. This is directly comparable 
      to the current standard methodology using whole sections. The use of TMA 
      technology offers several advantages over existing full-section methods in terms 
      of cost, quality control, facilitation of future research and the facility to 
      provide a high-throughput testing methodology.
FAU - Graham, A D
AU  - Graham AD
AD  - Department of Pathology, NHS Lothian, University Hospitals Division, Royal 
      Infirmary, Edinburgh, UK.
FAU - Faratian, D
AU  - Faratian D
FAU - Rae, F
AU  - Rae F
FAU - Thomas, J St J
AU  - Thomas JS
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - England
TA  - Histopathology
JT  - Histopathology
JID - 7704136
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (DNA, Neoplasm)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
CIN - Histopathology. 2009 Jun;54(7):901. PMID: 19635107
MH  - Adenocarcinoma/genetics/metabolism
MH  - Adenocarcinoma, Mucinous/genetics/metabolism
MH  - Biomarkers, Tumor/metabolism
MH  - Breast Neoplasms/genetics/*metabolism
MH  - Carcinoma, Lobular/genetics/metabolism
MH  - DNA, Neoplasm/analysis
MH  - Female
MH  - Humans
MH  - *Immunohistochemistry
MH  - *In Situ Hybridization, Fluorescence
MH  - Prospective Studies
MH  - Receptor, ErbB-2/*metabolism
MH  - Reproducibility of Results
MH  - Tissue Array Analysis/economics/*methods
EDAT- 2008/05/23 09:00
MHDA- 2008/07/04 09:00
CRDT- 2008/05/23 09:00
PHST- 2008/05/23 09:00 [pubmed]
PHST- 2008/07/04 09:00 [medline]
PHST- 2008/05/23 09:00 [entrez]
AID - HIS3047 [pii]
AID - 10.1111/j.1365-2559.2008.03047.x [doi]
PST - ppublish
SO  - Histopathology. 2008 Jun;52(7):847-55. doi: 10.1111/j.1365-2559.2008.03047.x.